CDXS
$18.11
Codexis
($.46)
(2.48%)
CDXS
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $0.00
Revenue:  $22.82 Mil
Tuesday
Feb 25
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, November 05, 2019

What do you expect when CDXS reports earnings?
Beat
Meet
Miss

Where is CDXS's stock price going from here?
Up
Flat
Down
Stock chart of CDXS
Analysts
Summary of analysts' recommendations for CDXS
Score
Grade
Pivots
Resistance
$19.23
$18.96
$18.54

$18.26

Support
$17.84
$17.57
$17.14
Tweet
Growth
Description
Codexis, Inc. is a provider of optimized biocatalysts. Biocatalysts are enzymes or microbes that initiate or accelerate chemical reactions. Biocatalysts can make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The Company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. Codexis is based in Redwood City, California with additional offices in Budapest, Hungary; Singapore; and Bangalore, India.
Peers
Alexion PharmaceuticalsIncyteExact SciencesCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex